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ABSTRACT
Introduction: Fingolimod was the first oral
therapy approved for the treatment of
relapsing-remitting multiple sclerosis (RRMS).
Due to its action on cardiac sphingosine
1-phosphate receptors, fingolimod is leading
to a transient decrease in heart rate (HR) and the
occurrence of rare and asymptomatic
self-limited atrioventricular (AV) blocks. This
German non-interventional clinical study
aimed to assess the cardiac safety profile in
RRMS patients during at least 6 h after the
initial treatment or restart after interruption of
fingolimod in real-world settings.
Methods: The GoCARD study (German
National Health Authorities, BfArM,
CFTY720DDE18, NIS334) was a prospective,
multi-center non-interventional study which
was conducted in neurological and other
medical practices or hospitals, qualified to
routinely assess electrocardiogram (ECG)
findings. Data were collected through
interviews, clinical evaluations (notably ECGs),
and laboratory tests. Medical history, vital signs,
and a 12-lead ECG were assessed before
fingolimod administration. After the first dose,
a 6 h ECG was performed and vital signs (blood
pressure and HR) were measured hourly. The
occurrence of bradycardia (HR B45 beats per
minute [BPM]), AV blocks (2nd degree Mobitz
type I or higher), and corrected QT interval
(QTc) intervals was also documented.
Results: More than 95% of physicians adhered
to the cardiac monitoring recommendations.
The observation of 217 patients in 42 study
centers showed that while 35.9% of the
patients had any cardiac risk profile, none of
them experienced a bradycardia during the 6 h
post-dose observation. Overall, only 1.8% of all
patients displayed bradycardia (HR B45 BPM)
during 6 h after treatment initiation.
Moreover, in this cohort, none of the patients
showed a new or persistent onset AV block
(2nd degree Mobitz type I or higher) or QTc
C500 ms.
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Conclusion: Altogether, these data confirm
that the first-dose observation after fingolimod
initiation is usually uneventful (even in
patients with pre-existing cardiovascular risk
factors of this cohort) and that the rarely
observed events remained asymptomatic and
self-limited.
Funding: Novartis Pharma GmbH, Nu¨rnberg,
Germany.
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INTRODUCTION
Multiple sclerosis (MS) is a demyelinating
disease of the central nervous system leading
to inflammation and destruction of myelin and
axons [1]. A worldwide average incidence of 2.5
per 100,000 people with a variance of 1.1–4.0
and a prevalence of 30.0 per 100,000 people
with a variance of 5.0–80.0 is estimated (Word
Health Organization, 2008). The
relapsing-remitting (RRMS) course of the
disease is typically characterized by recurrent
acute episodes with neurologic symptoms,
followed by complete or partial recovery.
Fingolimod (FTY720, brand name Gilenya
Novartis Pharma AG, Basel, Switzerland) has
been approved for the treatment of RRMS. The
safety profile of fingolimod has been proven by
treatment of over 30,000 MS patients in clinical
studies. Altogether, worldwide, more than
148,000 patients were treated with the
substance, according to an experience of
316,000 patient years (data obtained from Q1
Novartis Pharmaceuticals Interim Financial
Report, April 2016).
Due to the expression of sphingosine
1-phosphate receptors on cardiomyocytes, it
was known that the first dose of fingolimod
may lead to a transient, usually asymptomatic
bradycardia and may possibly trigger rare and
self-limited atrioventricular-blocks (AV blocks)
[2–4]. Therefore, the European Medicines
Agency recommended a 6 h continuous
cardiac monitoring after the first
administration of fingolimod.
Therefore, the aims of this
non-interventional study (NIS) were the
following: (1) to assess the cardiac risk profile
in RRMS patients who intended to be treated
with fingolimod, (2) to assess the cardiac safety
profile in RRMS patients during at least 6 h after
the initial treatment or restart after
interruption, and (3) to assess the adherence
of treating physicians regarding the new
cardiovascular monitoring.
METHODS
Subjects and Study Design
This prospective, multi-center NIS (registered by
the German National Health Authorities,
[BfArM], CFTY720DDE18, NIS334) was
conducted in neurological and other medical
practices or hospitals in Germany, qualified to
routinely assess electrocardiogram (ECG)
findings and to conduct first treatment with
fingolimod, including the appropriate
cardiovascular monitoring. The patient was
observed for 6 h or longer, depending on
whether or not cardiac abnormalities arose.
Only data of patients under therapy with
fingolimod under the routine treatment
conditions were documented on the day of
the visit and evaluated. If any adverse events
(AEs) were reported after the 6 h observation
period, a documentation of these events was
obligatory. The prescription of fingolimod was
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solely based on the treatment decision of the
physician. 217 patients with a mean age of
39.8 ± 9.8 years were enrolled at 42 German
study centers.
Ethics Statement
All procedures were in accordance with the
ethical standards of the responsible committee
on human experimentation (institutional and
national) and with the Helsinki Declaration of
1964, as revised in 2013. The protocol was
approved by an independent Ethics Committee.
All patients gave written informed consent
before any study-related procedures were
performed.
Data Collection
Data were collected through interviews, clinical
evaluations (notably ECGs), and laboratory
tests. Each study site was equipped with the
ECG-device Custo Cardio 100/110/130
(Customed GmbH, Ottobrun, Germany), a
12-lead-continuous-ECG-digital recorder. The
ECG recordings were pseudonymized and
immediately transmitted via the Internet to a
central reading site (Cormed Services Ltd.,
Dinslaken, Germany) for evaluation. Medical
history, laboratory values, MS history,
Expanded Disability Status Scale [5],
cardiologic parameters, body mass index, vital
signs, and a pre-dose 12-lead ECG were assessed
before fingolimod administration. After the first
dose, a 6 h continuous ECG was performed and
vital signs (blood pressure and heart rate [HR])
were measured and documented hourly. The
occurrence of bradycardia (HR B45 BPM), AV
blocks (2nd degree Mobitz type I or higher), and
corrected QT interval (QTc) interval was also
documented.
Statistical Analysis
Outcomes of this study were the incidence with
95% confidence intervals of the aforementioned
cardiac parameters, occurring during or at the
end of the 6 h observation period after therapy
start with fingolimod. The analysis was
performed using the SAS software version 9.2
(SAS Institute Inc., Cary, NC, USA). The number
of participating centers and enrolled patients
(42 centers and 217 patients) was lower than
expected (2000 patients), resulting in a
relatively small sample size. Therefore, only
descriptive statistics are presented in this paper.
RESULTS
From February 2012 to April 2015, 217 patients
were enrolled at 42 study centers (5.2 ± 5.5
patients/center). The mean age of the 58 males
(26.7%) and 159 females (73.3%) included was
39.8± 9.8 years (see Table 1). Data onMS history
are also summarized in Table 1. For the
evaluation of the cardiac risk profile, the history
of cardiovascular risk factors in patients and their
families was assessed. A family history of
cardiovascular risk factors was reported in 43.8%
of the patients, mostly hypertension (66 patients,
30.4%) and diabetes mellitus (35 patients,
16.1%). A cardiovascular risk factor was directly
observed in 78 patients (35.9%), mostly tobacco
use (40 patients, 18.4%), overweight (27 patients,
12.4%), and hypertension (24 patients, 11.1%).
Ten patients (4.6%) had a history of cardiac
arrhythmias. Twenty nine (13.4%) of the 217
patients enrolled took concomitantly
cardiovascular medication, mainly
antihypertensive (25 patients, 11.5%), beta
blockers (two patients, 0.9%), calcium-channel
blockers (one patient, 0.5%), or lipid-lowering
drugs (eight patients, 3.7%).
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ECG examinations were mainly performed
by cardiologists (61.7% and 62.7%), followed by
neurologists (16.2% and 16.6%), general
practitioners (13.1% and 10.6%), and
specialists in internal medicine (8.1% and
8.3%). Overall, more than 95% of physicians
adhered to the cardiac monitoring
recommendations.
Course of blood pressure and HR course at
baseline and during the 6 h observation period
are summarized in Fig. 1a and b. The detailed
HR course is also represented in Table 2. During
the observation period, blood pressure
remained relatively stable; only a slight
decrease in the mean blood pressure (systolic
and diastolic) was observed (Fig. 1a). The
lowest mean systolic blood pressure
(120.4 ± 13.9 mmHg) was observed, 2 h after
treatment start and 5 h after treatment start, the
lowest mean diastolic blood pressure
(76.7 ± 10.0 mmHg). Patients receiving the
first dose of fingolimod experienced, on
Table 1 Characteristics of study participants
Demographic data N5 217
Age (years)
n, Mean ± SD 217, 39.8 ± 9.8
Sex
Male, n (%) 58 (26.7%)
Female, n (%) 159 (73.3%)
BMI (kg/m2)
n, Mean ± SD 207, 25.3 ± 5.0
MS history
History of highly active RRMS n (%)
Yes 217 (100.0)
No 0 (0.0)
Time of ﬁrst diagnosis prior to treatment start (years)
n, Mean ± SD 69, 8.1 ± 6.5
EDSS
n, Mean ± SD 108, 3.06 ± 1.66
Median (min; max) 3.00 (0.00; 8.00)
1st quartile 2.00
3rd quartile 4.00
History of cardiovascular risk factors
Patients with a family history of at least
one risk factora, n (%)
95 (43.8)
Patients with any risk factorb, n (%) 78 (35.9)
Tobacco use 40 (18.4)
Overweight 27 (12.4)
Hypertension 24 (11.1)
Elevated blood lipids 12 (5.5)
Patients with concomitant
cardiovascular medication, n (%)
29 (13.4)
Antihypertensive drugs 25 (11.5)
Lipid-lowering drugs 8 (3.7)
Beta blockers 2 (0.9)




Demographic data N5 217
Antiplatelet drugs 1 (0.5)
Calcium-channel blockers that may
lower the heart rate
1 (0.5)
Patients with history of cardiac
arrhythmias, n (%)
10 (4.6)
Patients with history of antiarrhythmic
therapies, n (%)
11 (5.1)
Patients with cardiac abnormalities in
baseline ECG, n (%)
2 (0.9)
BMI body mass index, ECG electrocardiogram, EDSS
expanded disability status scale, MS multiple sclerosis,
RRMS relapsing-remitting multiple sclerosis, SD standard
deviation
a Hypertension, diabetes mellitus, or elevated blood lipids
in family history
b Patients can have multiple risk factors
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average, a slight and transient decline in HR
(Table 2; Fig. 1b). These patients had a
maximum mean decline in HR of 9.2 beats per
minute (BPM) from 74.9 ± 11.5 to 65.8 ± 9.9
BPM with the lowest values measured at 5 h
after application.
Overall, 33 patients (15.2%) were
documented with cardiac events during or at
the end of the observation period, summarized
in Table 3 (including asymptomatic blood
pressure increase or HR increase) [data on file,
(Novartis Pharma GmbH, Nu¨rnberg, Germany)].
None of the patients displayed a new or
persistent onset AV block [2nd degree (Mobitz
type I) or 3rd degree] or QTc C500 ms.
Bradycardia, defined as a decrease in HR \45
BPM during or at the end of the observation
period, was reported for four and three patients
(1.8% and 1.4%, respectively). ‘‘Other’’ cardiac
events were documented for nine and four
patients (4.3% and 1.8%, respectively) during
or at the end of the observation period. These
events mostly referred to a low HR which did,
however, not meet the criteria of a bradycardia
(45–60 BPM) or AV block other than 2nd or 3rd
degree (i.e. AV-block 1st degree). None of these
Fig. 1 Evolution of vital signs and cardiac events during
and after the 6 h monitoring post-treatment initiation.
a Systolic and diastolic blood pressure course at baseline
and during the 6 h observation period (in mmHg, each
value represents the mean ± SD, n = 215). b Heart rate
course at baseline and during the 6 h observation period
(in BPM, each value represents the mean ± SD, n = 215).
BPM beats per minute, SD standard deviation
Table 2 Heart rate course (in BPM) at baseline and during the 6 h observation period (n = 215)
Time point Mean SD Min 1st quartile Median 3rd quartile Max
Baseline 74.9 11.5 48 58.0 75 81.0 104
After 1 h 73.1 10.9 43 57.0 72 80.0 105
After 2 h 69.2 10.6 44 53.0 69 75.0 110
After 3 h 67.1 11.1 44 50.0 66 73.0 108
After 4 h 65.9 11.0 43 49.0 65 71.0 109
After 5 h 65.8 9.9 42 52.0 65 71.0 100
After 6 h 66.9 10.1 44 52.0 66 73.0 98
BPM beats per minute, SD standard deviation
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patients had any cardiovascular risks/history or
took HR-lowering co-medication.
DISCUSSION
Here, we analyze the cardiac side effects after
the first dose of fingolimod in everyday practice
and confirm the well-known favorable cardiac
safety profile of this compound in a real-world
setting. None of the few cardiac events in this
study required medical attention. The positive
cardiac safety profile also extended to blood
pressure analyses with only mild changes in
systolic and diastolic blood pressure and even to
the 35.9% of patients in the study with any
cardiac risk factor (mainly tobacco use,
overweight, hypertension, or patients taking
cardiovascular co-medications, see Table 1). The
Table 3 Patients with cardiac events during and/or at the end of the 6 h observation period
During the
observation period







Overall population 31 (14.3) 7 (3.2)
cardiovasc. risk factors 9 (4.1) 0 (0.0)
New onset AV-block 3rd degreeb
Overall population 0 (0.0)
cardiovasc. risk factors 0 (0.0)
Persistent onset AV-block 2nd degree (Mobitz type I) or higher
Overall population 0 (0.0)
cardiovasc. risk factors 0 (0.0)
Bradycardia (heart rate <45 bpm)c
Overall population 4 (1.8) 3 (1.4)
cardiovasc. risk factors 0 (0.0) 0 (0.0)
QTc interval ‡500 msd
Overall population n.a. 0 (0.0)
cardiovasc. risk factors n.a. 0 (0.0)
Other cardiac eventse
Overall population 9 (4.1) 4 (1.8)
cardiovasc. risk factors 3 (1.4) 0 (0.0)
AV block atrioventricular block, BPM beats per minute, QTc corrected QT interval
a Including asymptomatic blood pressure increase (data on ﬁle, [Novartis Pharma GmbH, Nu¨rnberg, Germany])
b Information was missing for two Patients (0.9%)
c Information was missing for one patient (0.4%)
d Information was missing for nine patients (4.1%)
e Referred to a low heart rate which does not meet the criteria of a bradycardia or 1st degree AV Blocks
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particular strength of this non-interventional
study is that it encompasses patients with
pre-existing cardiac risk factors, who are
excluded from the majority of clinical studies
investigating fingolimod. This cardiac safety
profile, including the observed episodes of
bradycardia and the few other cardiac events,
is consistent with the data of the first-dose
monitoring from pivotal phase III trials and
from a phase IIb multi-center study as well as
post-marketing experience from the ongoing
START Study (ClinicalTrials.gov identifier,
NCT01585298; a prospective, one-week,
multi-center, open-label study enrolling up to
7000 patients with RRMS in more than 250
centers in Germany, which already analyzed
data of 3.951 patients) [2, 3, 6–10]. The absence
of an increased QTc period is also consistent
with the previous findings from rat models [11].
Very encouraging is also the following result:
from the 35.9% of patients who shared any
cardiac risk profile (especially those having a
history of hypertension or arrhythmia), none
experienced bradycardia during the 6 h
post-dose observation, including those who
were under HR-lowering co-medication.
Overall, only 1.8% of all patients in this small
cohort displayed bradycardia (HR B45 BPM)
during the 6 h post-dose observation. Analyses
from other studies in ‘‘real-life’’ settings provide
further evidence on fingolimod treatment
initiation. Data of the first study
(ClinicalTrials.gov identifier, NCT01497262),
which also enrolled RRMS patients taking
calcium-channel blockers and beta blockers
(n = 2417), showed an increased frequency of
bradycardia in patients receiving these
cardiovascular co-medications [4]. This
observation was not seen in our study, which
may be limited by its lower number of
participants. However, our results are in
agreement with the data of other recent
observations in real-life settings. For example,
data of an Italian study assessing the safety and
tolerability of fingolimod after first dose
(n = 906) revealed that the concomitant use of
drugs which may cause bradycardia or
otherwise influence cardiac conduction was
not associated with cardiac events during the
first-dose observation [12]. Other studies in
real-life settings also demonstrate the rare
occurrence of cardiac events after the first dose
of fingolimod and their self-limited character
[2, 3, 12–17], thus corroborating the very
favorable cardiac safety profile of fingolimod.
Another strength of this study refers to the
ECG data collection obtained in real-world
settings which prove that the recommended
cardiovascular observation after the first
administration of fingolimod in office-based
settings is feasible and also adhered to.
Possible limitations of this study lie in the
lower than expected number of recruited
patients. It was planned to include
approximately 2000 patients over a 3-year
period. Only 217 patients were enrolled at 42
study centers possibly due to competing studies
and the widespread use of fingolimod outside of
study settings in everyday practice. This lower
number of enrolled patients may affect the
detection of possible rare AEs. Yet, few missing
data and good compliance to the
recommendations in the summary of product
characteristics during this NIS indicate a good
reliability of the results.
CONCLUSION
In summary, these data confirm: (1) the
feasibility of ECG monitoring for the
fingolimod initiation in real-life settings and
(2) that the first-dose observation after the
fingolimod initiation is usually uneventful
(even in patients with pre-existing
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cardiovascular risk factors of this cohort). Rare
cardiac events remained asymptomatic and
self-limited.
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